AIM ImmunoTech signed material transfer and research agreement with Japan’s National Institute of Infectious Diseases and Shionogi & Co to test Ampligen as potential vaccine adjuvant for COVID-19
|

AIM ImmunoTech signed material transfer and research agreement with Japan’s National Institute of Infectious Diseases and Shionogi & Co to test Ampligen as potential vaccine adjuvant for COVID-19

On Jul. 6, 2020, AIM ImmunoTech announced that it had signed a material transfer and research agreement with…